MedPath

Prediction Model of Occult Omental Metastasis in Patients With Gastric Cancer

Recruiting
Conditions
Gastric Cancer
Omental Metastasis
Registration Number
NCT06405009
Lead Sponsor
Northern Jiangsu People's Hospital
Brief Summary

A complete omentectomy is typically recommended during radical total gastrectomy for gastric cancer, though its impact on survival remains unclear. This study aimed to assess the frequency and risk factors of metastases in the greater omentum in gastric cancer patients undergoing gastrectomy. It will involve a single prospective cohort of consecutive patients who underwent total gastrectomy with complete en bloc omentectomy and modified D2 lymphadenectomy. Post-surgery, the omentum will dissect from the gastrectomy specimen beyond the gastroepiploic vessels and examine separately for pathological assessment. The primary outcome will focus on the detection of omental metastases.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
450
Inclusion Criteria
  1. pathological confirmation of gastric cancer
  2. eligibility for surgical intervention
  3. undergoing first rectal cancer surgery
  4. acquisition of written informed consent from patients and their families
  5. no history of hypertrophic scar or allergic predispositions
Exclusion Criteria
  1. absence of postoperative pathology of the omentum
  2. diagnosis of multiple primary malignancies
  3. intraoperative discovery of widespread implant metastases within the abdominal cavity
  4. severe comorbidities

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
patients with omental metastasesup to 2 weeks after gastric cancer surgery

After the operation, the postoperative pathological examination of the patient indicated the presence of omental metastases

patients without omental metastasesup to 2 weeks after gastric cancer surgery

After surgery, pathological examination confirmed no omental metastases

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Yifan Cheng

🇨🇳

Yangzhou, Jiangsu, China

Yifan Cheng
🇨🇳Yangzhou, Jiangsu, China
Yifan Cheng
Contact
8615267258283
cyfchengyifan528@sina.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.